Top

Published in:

01-10-2017 | Original Research Article

Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study

Authors: Kieran L. Quinn, Erin M. Macdonald, Muhammad M. Mamdani, Christina Diong, David N. Juurlink, for the Canadian Drug Safety and Effectiveness Research Network (CDSERN)

Published in: Drug Safety | Issue 10/2017

Abstract

Background

Statins are commonly prescribed for the secondary prevention of ischemic stroke, but there is conflicting evidence as to whether they increase the risk of intracranial hemorrhage. Lipophilic statins cross the blood–brain barrier more freely than hydrophilic statins and may therefore increase the risk of intracranial hemorrhage.

Objective

To determine whether, in older patients following ischemic stroke, receipt of lipophilic statins was associated with differences in the risk of intracranial hemorrhage.

Methods

We conducted a population-based nested case-control study linking multiple healthcare databases between 1 April, 2001 and 31 March, 2015 in Ontario, Canada. Cases were Ontarians aged 66 years or older receiving a statin within 100 days preceding the development of intracranial hemorrhage within 1 year following ischemic stroke. Each case was matched with up to four controls who experienced ischemic stroke not complicated by intracranial hemorrhage but who also received a statin. We classified statins as lipophilic (atorvastatin, simvastatin, lovastatin, fluvastatin, and cerivastatin) or hydrophilic (pravastatin and rosuvastatin) based on their octanol/water partition coefficients. We calculated the odds ratio for the association between intracranial hemorrhage and receipt of lipophilic statins, with hydrophilic statins as the reference group.

Results

We identified 2766 individuals who experienced intracranial hemorrhage during statin therapy after ischemic stroke and 11,060 matched controls. Relative to hydrophilic statins, lipophilic statins were not associated with an increased risk of intracranial hemorrhage (adjusted odds ratio 1.07; 95% confidence interval 0.97–1.19).

Conclusion

Among patients treated with a statin following ischemic stroke, the risk of intracranial hemorrhage is not influenced by statin lipophilicity.

Available only for authorised users

Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889–934.CrossRefPubMed

Voelker R. News from the Centers for Disease Control and Prevention: cholesterol-lowering drugs taken by 28% of US population. JAMA. 2015;313(8):787.

Ovbiagele B, Schwamm LH, Smith EE, Hernandez AF, Olson DM, Pan W, et al. Recent nationwide trends in discharge statin treatment of hospitalized patients with stroke. Stroke. 2010;41(7):1508–13.CrossRefPubMed

Amarenco P, Bogousslavsky J, Callahan A, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–59.CrossRefPubMed

Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104(2):109–24.CrossRefPubMed

Golomb BA, Evans MA. Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008;8(6):373–418.CrossRefPubMedPubMedCentral

Collins R, Armitage J, Parish S, Sleight P. Peto R; Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363(9411):757–67.CrossRefPubMed

Scheitz JF, Seiffge DJ, Tütüncü S, Gensicke H, Audebert HJ, Bonati LH, et al. Dose-related effects of statins on symptomatic intracerebral hemorrhage and outcome after thrombolysis for ischemic stroke. Stroke. 2014;45(2):509–14.CrossRefPubMed

Vergouwen MDI, de Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke. 2008;39(2):497–502.CrossRefPubMed

10.

Goldstein LB, Amarenco P, Zivin J, Messig M, Altafullah I, Callahan A, et al. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2009;40(11):3526–31.CrossRefPubMed

11.

Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.CrossRefPubMed

12.

Hackam DG, Austin PC, Huang A, Juurlink DN, Mamdani MM, Paterson JM, et al. Statins and intracerebral hemorrhage: a retrospective cohort study. Arch Neurol. 2012;69(1):39–45.CrossRefPubMed

13.

Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation. 2011;124(20):2233–42.CrossRefPubMed

14.

McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke. 2012;43(8):2149–56.CrossRefPubMed

15.

Molina CA, Selim MH. Continued statin treatment after acute intracranial hemorrhage: fighting fire with fire. Stroke. 2013;44(7):2062–3.CrossRefPubMed

16.

Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res. 1994;11(2):305–11.CrossRefPubMed

17.

García-Román N, Alvarez AM, Toro MJ, Montes A, Lorenzo MJ. Lovastatin induces apoptosis of spontaneously immortalized rat brain neuroblasts: involvement of nonsterol isoprenoid biosynthesis inhibition. Mol Cell Neurosci. 2001;17(2):329–41.CrossRefPubMed

18.

Kirsch C, Eckert GP, Mueller WE. Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol. 2003;65(5):843–56.CrossRefPubMed

19.

Prinz V, Laufs U, Gertz K, Kronenberg G, Balkaya M, Leithner C, et al. Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke. 2008;39(2):433–8.CrossRefPubMed

20.

Juurlink DN, Preyra C, Croxford R, Chong A, Austin PC, Laupacis A, et al. Canadian institute for health information discharge abstract database: a validation study. Toronto: Institute for Clinical Evaluative Sciences; 2006.

21.

Fralick M, Macdonald EM, Gomes T, Antoniou T, Hollands S, Mamdani MM, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ. 2014;349:g6196.CrossRefPubMedPubMedCentral

22.

Gomes T, Mamdani MM, Juurlink DN. Macrolide-induced digoxin toxicity: a population-based study. Clin Pharmacol Ther. 2009;86(4):383–6.CrossRefPubMed

23.

Igel M, Sudhop T, von Bergmann K. Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol. 2002;42(8):835–45.CrossRefPubMed

24.

Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–51.CrossRefPubMed

25.

Glynn RJ, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360(18):1851–61.CrossRefPubMedPubMedCentral

26.

Goldstein LB, Amarenco P, Szarek M, Callahan A, Hennerici M, Sillesen H, et al. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology. 2008;70(24 Pt 2):2364–70.CrossRefPubMed

27.

Bar B, Hemphill JC. Charlson comorbidity index adjustment in intracerebral hemorrhage. Stroke. 2011;42(10):2944–6.CrossRefPubMedPubMedCentral

Title: Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study
Authors: Kieran L. Quinn
Erin M. Macdonald
Muhammad M. Mamdani
Christina Diong
David N. Juurlink
for the Canadian Drug Safety and Effectiveness Research Network (CDSERN)
Publication date: 01-10-2017
Publisher: Springer International Publishing
Published in: Drug Safety / Issue 10/2017
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI: https://doi.org/10.1007/s40264-017-0552-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study

Abstract

Background

Objective

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2017

17th ISoP Annual Meeting “Pharmacovigilance in the 21st Century” Liverpool, UK 15–18 October, 2017

The New Phase of ISoP

Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database

A New Erice Report Considering the Safety of Medicines in the 21st Century

Statin Therapy and Risk of Intracranial Hemorrhage in Patients with Ischemic Stroke

Patients’ Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana